Roche News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

19.12.24	Genentech's Phase IIb Study Of Prasinezumab In Early-Stage Parkinson's Disease Misses Main Goal (RTTNews)
19.12.24	Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease (Roche Holding AG)
18.12.24	Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution (Roche Holding AG)
13.12.24	Roche Announces Approval Of Vabysmo Prefilled Syringe In The EU - Quick Facts (RTTNews)
13.12.24	Roche Gets CE Mark For New Molecular Cobas 6800/8800 Systems - Quick Facts (RTTNews)
13.12.24	Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities (Roche Holding AG)
10.12.24	New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma (Roche Holding AG)
10.12.24	Genentech's Columvi And Lunsumio Data Highlight Potential To Improve Lymphoma Outcomes (RTTNews)
09.12.24	Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash (Roche Holding AG)
08.12.24	Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma (Roche Holding AG)
05.12.24	FDA Accepts Genentech's Columvi Combo SBLA For R/R Diffuse Large B-Cell Lymphoma Treatment (RTTNews)
05.12.24	FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma (Roche Holding AG)
26.11.24	Roche To Acquire Poseida For Up To $1.5 Bln (RTTNews)
26.11.24	Genentech:Phase III Study Of Tiragolumab Combination In Advanced Lung Cancer Fails To Meet Main Goal (RTTNews)
26.11.24	Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies (Roche Holding AG)
26.11.24	Roche reports update on Phase III SKYSCRAPER-01 study results (Roche Holding AG)
25.11.24	Roche Gets FDA Approval For First Companion Diagnostic For HER2 Treatment In Biliary Tract Cancer (RTTNews)
18.11.24	Roche's VENTANA FOLR1 (FOLR1-2.1) RxDx Assay Gets CE Mark In Ovarian Cancer Treatment (RTTNews)
12.11.24	Flare Therapeutics Enters Discovery Collaboration With Roche - Quick Facts (RTTNews)
05.11.24	Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024 (Roche Holding AG)
31.10.24	Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease (Roche Holding AG)
31.10.24	New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer (Roche Holding AG)
23.10.24	Roche Group Sales In Q3, 9M Rise; Confirms FY24 Outlook (RTTNews)
23.10.24	[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months (Roche Holding AG)
19.10.24	ELEVATUM Study:Roche' Vabysmo Enhances Vision In Underrepresented Diabetic Macular Edema Populations (RTTNews)
18.10.24	Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study (Roche Holding AG)
18.10.24	Astellas Pharma's VYLOY Receives FDA Approval For Treatment Of Advanced Gastric And GEJ Cancer (RTTNews)
14.10.24	Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate (Roche Holding AG)
11.10.24	FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (Roche Holding AG)
11.10.24	FDA Approves Genentech's Itovebi For Advanced Breast Cancer With PIK3CA Mutation (RTTNews)
10.10.24	Tempest Inks Deal With Roche To Support Advancement Of Amezalpat Combination Therapy (RTTNews)
10.10.24	Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY (Roche Holding AG)
30.09.24	Roche Sees Sales Momentum To Continue Into 2025; Aims To Deliver 20 New Medicines (RTTNews)
26.09.24	Roche's Gazyva/Gazyvaro Shows Superiority To Standard Therapy In Phase III Lupus Nephritis Study (RTTNews)
26.09.24	Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis (Roche Holding AG)
24.09.24	Roche Unveils Cobas Respiratory Flex Test For Simultaneous Detection Of 12 Respiratory Viruses (RTTNews)
24.09.24	Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses (Roche Holding AG)
23.09.24	WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions (Roche Holding AG)
19.09.24	Roche's Xofluza Reduces Influenza Transmission In Phase III Study (RTTNews)
19.09.24	Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses (Roche Holding AG)
16.09.24	Roche's OCREVUS ZUNOVO Gets FDA Approval To Treat Relapsing And Progressive Multiple Sclerosis (RTTNews)
16.09.24	FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis (Roche Holding AG)
13.09.24	FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy (Roche Holding AG)
13.09.24	FDA Oks Genentech's Tecentriq Hybreza As First & Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy (RTTNews)
10.09.24	Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation (Roche Holding AG)
09.09.24	Roche Expands Digital Pathology With More Than 20 AI Algorithms From Eight New Partners (RTTNews)
04.09.24	Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis (Roche Holding AG)
02.09.24	Biotech Stocks Facing FDA Decision In September 2024 (RTTNews)
01.09.24	Weekly Biotech Buzz: BMRN Cuts Jobs, FDA Approves New Mpox Vaccine, MRK Halts 2 Keytruda Studies (RTTNews)
27.08.24	European Commission Approves Roche's PiaSky For Paroxysmal Nocturnal Hemoglobinuria (RTTNews)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

25.06.24		Roche kann EU-Zulassung für Multiple-Sklerose-Mittel an Land ziehen - Aktie sinkt dennoch
10.06.24		Roche-Aktie dennoch tiefer: EU-Kommission lässt Lungenkrebsmedikament Alecensa zu
21.05.24		Roche-Aktie schwächer: Roche-Übernahme von LumiraDx in prüfung - Inavolisib erhält "Breakthrough Therapy"-Status
11.12.23		Roche-Aktie etwas fester: Roche legt Studiendaten zu Kadcyla, Hemlibra, Columvi und Lunsumio vor
02.02.23		Roche-Aktie schwächer: Roche erreicht 2022 Prognose - Umsatz- und Gewinnrückgang im neuen Jahr erwartet
27.12.22		Roche-Aktie leichter: FDA lässt Roches Lymphom-Behandlung Lunsumio zu
16.09.22		Roche-Aktie gewinnt: Moody's hebt Bonitätseinstufung für Roche an
25.04.22		Roche-Aktie leichter: Umsatz übertrifft Erwartungen